semaglutide tablets novo nordisk launches Wegovy subscription for GLP-1 obesity drugs Novo Nordisk's weight-loss pill wins

doi: 10.1016/j.jacbts.2022.03.017, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 60

Chronic hyperglycemia is responsible for many complications, including cardiovascular disease, nerve damage (neuropathy), kidney damage (nephropathy), eye disease, unintentional weight loss (due to metabolism of fat and muscle, as cells do not have access to glucose to metabolize), and diabetic ketoacidosis

Some patients use semaglutide long-term as a chronic weight management tool, similar to blood pressure or diabetes medications

Less reputable sources may produce formulations with variable potency, which directly affects how quickly you notice results

Friedman JM

There is evidence that central GLP1 effects could be modulated by sex steroids